ClinicalTrials.gg
CompletedNCT00789633Updated Dec 17, 2018

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

A Phase 3 interventional study of Masitinib and Placebo in Pancreatic Cancer, sponsored by AB Science. Completed at 68 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2011, 14 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 234 studies in Pancreatic Neoplasms with a site in France — 52 open to participants now, 75 under way, 11 of them phase 3. Pancreatic Neoplasms · France.

Enrollment
41st of 181
353 · median 150
Started
2008
with 9 others
Phase 3
42 of 234
4 open now
Registered
32nd of 234
by date

Among the 234 studies in Pancreatic Neoplasms with a site in France, this one is the 41st largest by enrollment of the 181 interventional ones that give a count, is one of 10 that started in 2008, is one of 42 in phase 3, and was the 32nd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

52 of the 234 studies in Pancreatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Pancreatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.

Read the detailed description

Human pancreatic cancer overexpresses a number of important tyrosine kinase (TK) growth factors receptors and ligands, including expression of both PDGF and PDGF receptors. Drugs that can selectively inhibit TKs are likely to be of benefit in pancreatic cancer. Masitinib is a TK inhibitor, selectively and effectively inhibiting c-Kit (mast cell growth factor receptor), PDGF receptor, FGF receptor and to a lower extent the FAK kinases. Pre-clinical and clinical studies have shown that masitinib can reverse resistance of pancreatic tumor cell lines to gemcitabine. Based on pre-clinical and phase 2 clinical studies, masitinib can be considered as a good candidate to use in combination with gemcitabine in the treatment of pancreatic cancer.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Pancreatic cancer
  • Advanced pancreatic cancer
  • Metastatic pancreatic cancer
  • Gemcitabine
  • Chemo-naive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. or cytologically confirmed adenocarcinoma of the pancreas
  2. Chemo naïve patients with advanced/ disease
  3. Documented decision justifying non eligibility for surgical resection. The documentation of the non eligibility for surgical resection will be reviewed by an independent committee.
  4. Men and women, age >18 years
  5. Men and women of (entering the study after a confirmed menstrual period and who have a negative pregnancy test), must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of during the study and for 3 months after the last treatment intake.
  6. Patient should be able and willing to comply with study visits and procedures as per protocol.
  7. Patient should understand, sign, and date the written voluntary form at the screening visit prior to any protocol-specific procedures performed.

Main Exclusion Criteria:

  1. Patient treated for a cancer other than pancreatic cancer within 5 years before enrollment, with the exception of basal cell carcinoma or in situ cervical cancer
  2. Any condition that the physician judges could be detrimental to subjects participating in this study; including any deviations from normal clinical laboratory values or concurrent medical events Previous treatment
  3. Any anti-tumor therapy (any chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy) within 6 months prior to baseline
  4. Treatment with any agent within 4 weeks prior to baseline
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Masitinib & gemcitabine

    Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.

    Drug: Masitinib · Drug: Gemcitabine

  • Placebo comparator
    Placebo & gemcitabine

    Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.

    Drug: Placebo · Drug: Gemcitabine

Interventions

  • Masitinib at 9 mg/kg/day given orally twice daily

    Also known as: AB1010

  • DrugPlacebo

    Matching placebo given orally twice daily

  • Gemcitabine at 1000 mg/m2 by intravenous infusion

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to the date of death, assessed up to 60 months

Secondary outcomes

  1. Survival rate

    Defined as the proportion of patients alive at each time point, estimated with Kaplan-Meier distribution.

    Time frame: Every 24 weeks, assessed up to 60 months

  2. Progression Free Survival (PFS)

    Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by the investigator on CT scan according to RECIST 1.1 criteria.

    Time frame: From day of randomization to disease progression or death, whichever came first, assessed up to 60 months

07

Study locations

68 sites
  • Eastern Connecticut Hematology and Oncology (ECHO)
    Norwich, Connecticut 06360, United States
  • MD Anderson
    Orlando, Florida 32806, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • Medical & Surgical Specialists
    Galesburg, Illinois 61401, United States
  • Berkshire Hematology Oncology
    Pittsfield, Massachusetts 01201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Metro MN CCOP
    Saint Louis Park, Minnesota 55416, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • The Valley Hospital
    Paramus, New Jersey 07652, United States
  • Southeastern Medical Oncology Center
    Goldsboro, North Carolina 27534, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Teaching Hospital Brno-Bohunice
    Brno, 625 00, Czechia
  • Hospital Chomutov
    Chomutov, 430 12, Czechia
  • Oncology Surgery
    Kutná Hora, 284 30, Czechia
  • Department of Oncology Teaching Hospital Olomouc
    Olomouc, 775 20, Czechia
  • Teaching Hospital Královské
    Prague 10, 100 34, Czechia
  • Teaching Hospital Na Bulovce
    Prague 8, 180 81, Czechia
  • Hospital na Homolce
    Prague, 5 150 30, Czechia
  • CHU Amiens
    Amiens, 80000, France
  • Hôpital Privé d'Antony
    Antony, 92160, France
  • Institut Sainte-Catherine
    Avignon, 84000, France
  • Hôpital Jean Minjoz
    Besançon, France
  • Hôpital Saint-André
    Bordeaux, France
  • CHU de la Cavale Blanche
    Brest, 29600, France
  • CHU de Caen
    Caen, 14000, France
  • CHU Hôtel Dieu
    Clermont-Ferrand, 63000, France
  • Groupement Hospitalier Universitaire Nord - Beaujon
    Clichy, 92, France
  • CHU Henri Mondor
    Créteil, 94000, France
  • CHU Henri Mondor
    Créteil, France
  • Hôpital Victor Jousselin
    Dreux, France
  • Centre Gastro-Loire
    Gien, 45500, France
  • Institut Daniel Hollard
    Grenoble, 38000, France
  • CHD Les Oudairies
    La Roche sur Yon, 85925, France
  • Hôpital André Mignot
    Le Chesnay, 78150, France
  • Hôpital Robert Boulin
    Libourne, 33500, France
  • Hôpital Claude Huriez
    Lille, 59000, France
  • Centre Hospitalier de Longjumeau
    Longjumeau, 91164, France
  • Hôpital Privé Jean Mermoz
    Lyon, 69000, France
  • Hôpital Edouard Herriot
    Lyon, 69003, France
  • Centre Léon Bérard
    Lyon, France
  • Assistance Publique des Hôpitaux de Marseille
    Marseille, 13000, France
  • Hôpital Saint Joseph
    Marseille, 13000, France
  • Centre Hospitalier Belfort - Montbéliard
    Montbeliard, 25200, France
  • CHU Hôtel Dieu
    Nantes, 44000, France
  • Centre Catherine de Sienne
    Nantes, 44200, France
  • Hôpital de la Source
    Orléans, 45000, France
  • Groupe Hospitalier Diaconesse Croix Saint Simon
    Paris, 75000, France
  • Hôpital Tenon
    Paris, 75020, France
  • Hôpital Hôtel Dieu
    Paris, France
  • Hôpital Saint-Joseph
    Paris, France
  • Polyclinique Francheville
    Perigueux, 24000, France
  • Hôpital Haut-Lévêque
    Pessac, 33600, France
  • Hôpital Hautepierre
    Strasbourg, 67200, France
  • CHU Brabois
    Vandoeuvre lès Nancy, 54500, France
  • Hôpital Paul Brousse
    Villejuif, 94800, France
  • Hotel Dieu de France
    Beirut, Lebanon
  • Makassed General Hospital Tarik Jadide
    Beirut, Lebanon
  • Rafik Hariri University Hospital
    Beirut, Lebanon
  • Saint Georges Hospital UMC
    Beirut, Lebanon
  • Middle East Institute of Health- Bsaleem
    Metn, Lebanon
  • Saint Joseph Hospital Baouchrieh
    Metn, Lebanon
  • Hammoud Hospital University Medical Center
    Saida, Lebanon
  • Municipal Clinical Hospital
    Arad, 310013, Romania
  • County Hospital
    Baia-Mare, 430031, Romania
  • Emergency Clinical Hospital
    Constanta, 900591, Romania
  • Pelica Impex SRL Hospital
    Pelica Impex, 410548, Romania
  • County Hospital
    Satu Mare, 440056, Romania
08

References and documents

Publications

  • Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moye L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015 Jun;26(6):1194-1200. doi: 10.1093/annonc/mdv133. Epub 2015 Apr 9. PubMed 25858497 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Dec 2011, 36 months.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2008
First posted
Nov 13, 2008
StartActual
Nov 25, 2008
Primary completionActual
Dec 23, 2011
CompletionActual
Aug 31, 2012
Results delay requested
Dec 12, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00789633
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Nov 13, 2008
Start date
Nov 25, 2008
Primary completion
Dec 23, 2011
Completion
Aug 31, 2012
Last update
Dec 17, 2018

Study contacts

Gaël Deplanque, MD
principal investigator · Hôpital Saint Joseph, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion